Journal of the American Academy of Dermatology
Volume 62, Issue 4 , Pages 655-662, April 2010

Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation

  • Misha Rosenbach, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Sylvia Hsu, MD

      Affiliations

    • Department of Dermatology, Baylor College of Medicine, Houston, Texas
    • ,
  • Neil J. Korman, MD, PhD

      Affiliations

    • Department of Dermatology and the Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio
    • ,
  • Mark G. Lebwohl, MD

      Affiliations

    • Department of Dermatology, Mount Sinai School of Medicine, New York University, New York, New York
    • ,
  • Melodie Young, ARNP

      Affiliations

    • Modern Dermatology, Dallas, Texas
    • ,
  • Bruce F. Bebo Jr., PhD

      Affiliations

    • National Psoriasis Foundation, Portland, Oregon
    • ,
  • Abby S. Van Voorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests: Abby S. Van Voorhees, MD, Hospital of the University of Pennsylvania, 2 Rhoads, 3400 Spruce St, Philadelphia, PA 19104.

Accepted 14 May 2009. published online 10 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the National Psoriasis Foundation.

 Disclosure: Dr Van Voorhees has received grant support from Amgen, Astellas, and Warner Chilcott. She has been a consultant, advisory board member, or speaker for Amgen, Centocor, Connetics, Genentech, and Warner Chilcott and a drug safety monitoring board member for Synta. She is a major stockholder in Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech. She has been a clinical investigator for Amgen and Centocor. Dr Korman has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Ms Young has served on the advisory board or been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Rosenbach has no conflicts of interest to declare.

 Consensus: The medical board of the National Psoriasis Foundation reviewed and endorsed this manuscript by a majority vote.

PII: S0190-9622(09)00690-2

doi:10.1016/j.jaad.2009.05.048

Journal of the American Academy of Dermatology
Volume 62, Issue 4 , Pages 655-662, April 2010

Article Tools

* Image Usage & Resolution